癌症前线的希望,如何阻止这个有希望的目标前景?
Florian Schwalen1,2, Côme Ghadi1, Léonie Ibazizene3,4
1Université de Caen Normandie, CERMN UR4258, Normandie Univ, F-14000 Caen, France.
Journal of medicinal chemistry
|January 14, 2025
概括
研究人员正在探索UBE2N抑制剂用于癌症治疗. 非共价抑制剂比共价抑制剂更有前途,但药物特性必须在临床成功的早期评估.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- UBE2N蛋白对于DNA修复至关重要,也是抗癌药物开发的有希望的目标.
- 开发新的UBE2N抑制剂 (UBE2Ni) 对创新的癌症疗法至关重要.
研究的目的:
- 审查和指导新的UBE2N抑制剂的设计.
- 通过化学信息学分析UBE2N蛋白质结构和相互作用部位.
- 为了比较共价和非共价UBE2Ni,突出非共价方法的优势.
主要方法:
- 对UBE2N蛋白的化学信息结构分析.
- 对蛋白质相互作用部位的分析.
- 审查现有的UBE2N抑制剂及其发展阶段.
主要成果:
- 非共价UBE2Ni与共价抑制剂相比,具有潜在的优势,特别是在选择性方面.
- 早期评估化合物可用性的药物是必不可少的打击到领先的进展.
- UBE2Ni的药用动力学特性对治疗应用提出了重大挑战.
结论:
- 非共价UBE2N抑制剂为癌症治疗开发提供了一个有前途的途径.
- 早期解决药理动力学挑战对于将UBE2Ni转化为人类疗法至关重要.
- 需要进一步研究UBE2Ni的设计和可用性.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Electron Transport Chain: Complex I and II
10.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.9K


